These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37921681)

  • 1. Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis.
    Nicolas SE; Bear MD; Kanaan AO; Coman OA; Dima L
    Am J Ther; 2023 Nov-Dec 01; 30(6):e535-e542. PubMed ID: 37921681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
    Lebwohl MG; Kircik LH; Moore AY; Stein Gold L; Draelos ZD; Gooderham MJ; Papp KA; Bagel J; Bhatia N; Del Rosso JQ; Ferris LK; Green LJ; Hebert AA; Jones T; Kempers SE; Pariser DM; Yamauchi PS; Zirwas M; Albrecht L; Devani AR; Lomaga M; Feng A; Snyder S; Burnett P; Higham RC; Berk DR
    JAMA; 2022 Sep; 328(11):1073-1084. PubMed ID: 36125472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
    Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H;
    N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
    Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
    J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZORYVE
    Gupta AK; Ravi SP; Vincent K; Abramovits W
    Skinmed; 2023; 21(5):357-359. PubMed ID: 37945365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies.
    Thurston AW; Osborne DW; Snyder S; Higham RC; Burnett P; Berk DR
    Am J Clin Dermatol; 2023 Mar; 24(2):315-324. PubMed ID: 36422852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test.
    Snape SD; Wigger-Alberti W; Goehring UM
    Br J Dermatol; 2016 Sep; 175(3):479-86. PubMed ID: 27038440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    de Moraes-Souza R; Chahine Chater R; Pera Calvi I; Mesquita Y; Sarto R; Lapenda I; Figueiredo Pereira L; Moury L; Herranz-Pinto P
    Clin Drug Investig; 2024 Sep; 44(9):655-665. PubMed ID: 39172296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of Topical Roflumilast for the Treatment of Plaque Psoriasis.
    Pixley JN; Schaetzle T; Feldman SR
    Ann Pharmacother; 2023 Aug; 57(8):966-969. PubMed ID: 36420929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical Roflumilast for Plaque Psoriasis.
    O'Toole A; Gooderham M
    Skin Therapy Lett; 2023 Sep; 28(5):1-4. PubMed ID: 37734074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical roflumilast for the treatment of psoriasis.
    Drakos A; Vender R; Torres T
    Expert Rev Clin Immunol; 2023; 19(9):1053-1062. PubMed ID: 37243575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
    Stein Gold L; Adam DN; Albrecht L; Alonso-Llamazares J; Ferris LK; Gooderham MJ; Hong HC; Kempers SE; Kircik LH; Lebwohl M; Loo WJ; Nahm WK; Papp KA; Stewart D; Toth DP; Zirwas M; Krupa D; Snyder S; Burnett P; Higham R; Berk DR
    J Am Acad Dermatol; 2024 Aug; 91(2):273-280. PubMed ID: 38556093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
    Stein Gold L; Alonso-Llamazares J; Draelos ZD; Gooderham MJ; Kempers SE; Kircik LH; Lebwohl MG; Papp KA; Pariser DM; Toth DP; Yosipovitch G; Higham RC; Feng A; Berk DR
    Am J Clin Dermatol; 2023 Mar; 24(2):305-313. PubMed ID: 36370336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
    Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
    Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis.
    Ghani H; Podwojniak A; Tan IJ; Parikh AK; Sanabria B; Rao B
    Skin Res Technol; 2024 Sep; 30(9):e70041. PubMed ID: 39206797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
    Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
    J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
    Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
    J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
    Kircik LH; Alonso-Llamazares J; Bhatia N; Bukhalo M; Devani AR; Draelos ZD; DuBois J; Gooderham MJ; Kempers SE; Lain E; Lee M; Moore A; Murrell DF; Papp KA; Pariser DM; Sinclair R; Zirwas M; Burnett P; Higham RC; Krupa D; Berk DR
    Br J Dermatol; 2023 Sep; 189(4):392-399. PubMed ID: 37279795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
    Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
    J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study.
    Gooderham M; Kircik L; Zirwas M; Lee M; Kempers S; Draelos Z; Ferris L; Jones T; Saint-Cyr Proulx E; Bissonnette R; Bhatia N; Koppel R; Guenthner S; Eads K; Welgus H; Merritt C; Elias M; Navale L; Higham R; Droege M; Berk D
    J Drugs Dermatol; 2023 Feb; 22(2):139-147. PubMed ID: 36745371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.